ARE YOU AWARE OF THE UNKNOWN?
CUP (cancer of unknown primary) syndrome is defined as a cancer for which only metastases but no primary tumour or site of origin are detectable at the end of a diagnostic and clinical work-up.
HOW TO DISCOVER MORE ABOUT THE UNKNOWN?
Comprehensive genomic profiling (CGP) is a promising approach to translating genomic data into clinically useful information. It may help to identify more specific treatment options for patients with CUP.
CAN WE IMPROVE OUTCOMES IN CUP?
So far, data from standard chemotherapy-based clinical trials report median survival times of around one year or less. However, there are options for innovative new clinical trials that explore how to improve outcomes for patients today and in future.1,2
1. Fizazi K et al. Ann Oncol 2015; 26 (suppl 5): v133–8.
2. Hainsworth JD and Greco FA. American Society of Clinical Oncology Educational Book 38 (May 23, 2018) 20–5.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.